Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 25, 2015, Pages 7821-7826

  Barmada, Sami J ^a   Ju, Shulin ^b   Arjun, Arpana ^c   Batarse, Anthony ^c   Archbold, Hilary C ^a   Peisach, Daniel ^a   Li, Xingli ^a   Zhang, Yuxi ^a   Tank, Elizabeth M H ^a   Qiu, Haiyan ^d   Huang, Eric J ^d   Ringe, Dagmar ^e   Petsko, Gregory A ^e,f   Finkbeiner, Steven ^c,g,h  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c GLADSTONE INSTITUTES   (United States)

^d UNIVERSITY OF SAN FRANCISCO   (United States)

^e BRANDEIS UNIVERSITY   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

Author keywords

ALS; FTD; Neurodegeneration; RNA binding proteins; RNA decay

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; HUMAN UP FRAMESHIFT PROTEIN 1; MICRORNA; RED FLUORESCENT PROTEIN; RNA BINDING PROTEIN; RNA HELICASE; SHORT HAIRPIN RNA; SYNAPSIN I; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; TRANSACTIVATOR PROTEIN; UPF1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ARTICLE; AUTOREGULATION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOWN REGULATION; FRONTOTEMPORAL DEMENTIA; GENE SILENCING; IMMUNOCYTOCHEMISTRY; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA METABOLISM; SURVIVAL TIME; BIOLOGICAL MODEL; DRUG EFFECTS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

MAMMALIA;

AMYOTROPHIC LATERAL SCLEROSIS; CELL SURVIVAL; HUMANS; MODELS, BIOLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; NONSENSE MEDIATED MRNA DECAY; TRANS-ACTIVATORS;

EID: 84934900274     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509744112     Document Type: Article

References (48)

1. Huisman MHB, et al. (2011) Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 82(10): 1165-1170.
2. Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17-23.
3. Barmada SJ, Finkbeiner S (2010) Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: Disease-associated pathways. Rev Neurosci 21(4):251-272.
4. Barmada SJ, et al. (2014) Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol 10(8):677-685.
5. Bilican B, et al. (2012) Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci USA 109(15):5803-5808.
6. Barmada SJ, et al. (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30(2):639-649.
7. Nishimura AL, et al. (2014) Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS ONE 9(3):e91269.
8. Neumann M, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130-133.
9. Wils H, et al. (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 107(8):3858-3863.
10. Wang DB, et al. (2010) Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol Ther 18(12):2064-2074.
11. Vance C, et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323(5918):1208-1211.
12. Kwiatkowski TJ, Jr, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323(5918):1205-1208.
13. Neumann M, et al. (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132(Pt 11):2922-2931.
14. Lagier-Tourenne C, et al. (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15(11):1488-1497.
15. Ayala YM, et al. (2011) TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30(2):277-288.
16. Polymenidou M, et al. (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14(4):459-468.
17. Popp MW-L, Maquat LE (2013) Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet 47:139-165.
18. Zhou Y, Liu S, Liu G, Oztürk A, Hicks GG (2013) ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet 9(10):e1003895.
19. Ju S, et al. (2011) A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9(4):e1001052.
20. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431(7010):805-810.
21. Arrasate M, Finkbeiner S (2005) Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci USA 102(10):3840-3845.
22. Isken O, et al. (2008) Upf1 phosphorylation triggers translational repression during nonsense-mediated mRNA decay. Cell 133(2):314-327.
23. Skibinski G, Finkbeiner S (2013) Longitudinal measures of proteostasis in live neurons: Features that determine fate in models of neurodegenerative disease. FEBS Lett 587(8):1139-1146.
24. Miller J, et al. (2010) Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci 30(31):10541-10550.
25. Sephton CF, et al. (2010) TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 285(9):6826-6834.
26. Yang C, et al. (2014) Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 111(12):E1121-E1129.
27. Neumann M (2009) Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci 10(1):232-246.
28. Igaz LM, et al. (2011) Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 121(2):726-738.
29. Finkbeiner S (2011) Huntington's Disease. Cold Spring Harb Perspect Biol 3(6):pii: a007476.
30. Cheng Z, Muhlrad D, Lim MK, Parker R, Song H (2007) Structural and functional insights into the human Upf1 helicase core. EMBO J 26(1):253-264.
31. Durand S, et al. (2007) Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol 178(7): 1145-1160.
32. Chakrabarti S, et al. (2011) Molecular mechanisms for the RNA-dependent ATPase activity of Upf1 and its regulation by Upf2. Mol Cell 41(6):693-703.
33. Franks TM, Singh G, Lykke-Andersen J (2010) Upf1 ATPase-dependent mRNP disassembly is required for completion of nonsense-mediated mRNA decay. Cell 143(6):938-950.
34. Sun X, Perlick HA, Dietz HC, Maquat LE (1998) A mutated human homologue to yeast Upf1 protein has a dominant-negative effect on the decay of nonsense-containing mRNAs in mammalian cells. Proc Natl Acad Sci USA 95(17):10009-10014.
35. Huang C, et al. (2011) FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet 7(3):e1002011.
36. Janssens J, et al. (2013) Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol 48(1):22-35.
37. Qiu H, et al. (2014) ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest 124(3):981-999.
38. Medghalchi SM, et al. (2001) Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum Mol Genet 10(2):99-105.
39. Chen Y-Z, et al. (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74(6):1128-1135.
40. Lim SC, Bowler MW, Lai TF, Song H (2012) The Ighmbp2 helicase structure reveals the molecular basis for disease-causing mutations in DMSA1. Nucleic Acids Res 40(21):11009-11022.
41. de Planell-Saguer M, Schroeder DG, Rodicio MC, Cox GA, Mourelatos Z (2009) Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. Hum Mol Genet 18(12):2115-2126.
42. Molnar GM, et al. (1997) Association of the mammalian helicase MAH with the premRNA splicing complex. Proc Natl Acad Sci USA 94(15):7831-7836.
43. Yüce Ö, West SC (2013) Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response. Mol Cell Biol 33(2):406-417.
44. Izumi T, et al. (2013) Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol 87(20):11047-11062.
45. Gregersen LH, et al. (2014) MOV10 Is a 5′ to 3′ RNA helicase contributing to UPF1 mRNA target degradation by translocation along 3′ UTRs. Mol Cell 54(4):573-585.
46. Turner BJ, Talbot K (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85(1):94-134.
47. Jackson KL, et al. (2015) Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis. Gene Ther 22(1):20-28.
48. Grohmann K, et al. (2004) Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1). Hum Mol Genet 13(18):2031-2042.